PROCTER-&-GAMBLE
20.7.2021 10:02:14 CEST | Business Wire | Press release
P&G unveils its first paper bottle for Lenor in partnership with paper bottle company Paboco, announcing a pilot for Western Europe in 2022. The trial rollout will form the basis of a test and learn strategy to scale up paper packaging and incorporate it more widely across P&G’s portfolio.
P&G Fabric & Home Care with its popular brands including Ariel, Lenor, Tide, Downy, Fairy, and Cascade is fully committed to reducing plastics in its packaging. As part of its 2030 Ambition, P&G aims to reduce its use of virgin plastics by 50% by 2030. Fabric Care Europe has additionally committed to a 30% absolute plastics reduction by 2025 and to design for 100% recyclability by 2022 - it is well on track for both commitments. Home Care is committed to use no virgin plastics by 2025. Brand-led packaging alternatives and pilot schemes are a crucial element in the pathways to lowering environmental impact.
Paboco’s paper bottle technology is advancing quickly and promises to reduce and replace plastic content while lowering carbon footprint compared to conventional plastic packaging. This alternative form of packaging is increasingly viable and scaling at pace, backed by leading consumer goods companies and industry experts including The Coca-Cola Company, Carlsberg Group, The Absolut Company, L’Oréal, BillerudKorsnäs, and ALPLA united by the vision to create the world's first 100% bio-based and recyclable paper bottle at scale.
Senior Vice President of R&D for Global Fabric & Home Care Sector Jerry Porter explains:
“We’re very excited to join this group of packaging innovators. This is another milestone on our P&G Fabric & Home Care journey to innovate towards more sustainable packaging formats. Our chosen pilot brand Lenor has a great track record of incorporating recycled plastic into its packaging, already using up to 100% in its European transparent bottles. Now we aim to go a step further with bio-based packaging, which has a very promising future. We are delighted to be on this journey with our partners in the development of the next generations of paper bottles.”
Speaking on behalf of Paboco, interim CEO Gittan Schiöld noted:
“Our vision is to change this industry for good, and to create a world less dependent on plastic and without plastic waste, by designing for circularity and inventing packaging from bio-based materials. Storing liquids in paper is particularly challenging, but its successful adoption could have major benefits for the planet. Having P&G Fabric & Home Care category as a partner in the paper bottle community is a huge boost to that vision. Not only does it really add weight to the viability of the technology but brings with it P&G’s know-how to the table, offering new opportunities for scaling Paboco’s paper bottle technology.”
Lenor’s first paper bottle is a step on the bio-based packaging journey. The bottle already significantly reduces plastic compared to a bottle used today. The bottle is the first of its kind produced at scale, in its design and technology, made from sustainably sourced FSC-certified paper and initially a thin plastic barrier made from post-consumer recycled PET. Building on learnings from this milestone, future versions of the bottle will integrate the barrier into the paper lining to create a seamless, 100% bio-based bottle, fully recyclable in the paper stream.
All of P&G’s leadership brands, including Lenor, are expected to inspire responsible consumption by 2030 as part of the company’s Ambition 2030 sustainability goals.
To access images and other multimedia content, please visit here .
ENDS
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005201/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom